Anti-Tyro3 IgG Associates with Disease Activity and Reduces Efferocytosis of Macrophages in New-Onset Systemic Lupus Erythematosus

Table 1

The clinical and laboratory characteristics of new-onset and treatment-naïve SLE patients.

Variable	SLE patients
Gender (female/male, )	60/10
Age (, years)
Disease duration (months, median, IQR)	3.5 (1, 24)
SLEDAI ()
Fever (, %)	32 (45.7)
Arthritis (, %)	42 (60.0)
Rash (, %)	36 (51.4)
Oral ulcer (, %)	16 (22.9)
Alopecia (, %)	16 (22.9)
Vasculitis (, %)	5 (7.1)
Serositis (, %)	16 (22.9)
Photosensitivity (, %)	10 (14.3)
Raynaud’s phenomenon (, %)	13 (18.6)
Hematological (, %)	54 (77.1)
Lupus nephritis ( g/24 h) (, %)	31 (44.3)
Neuropsychiatric manifestations (, %)	1 (1.4)
Anti-dsDNA positive (, %)	63 (90.0)
Anti-Sm positive (, %)	17 (24.3)
Anti-SSA positive (, %)	38 (54.3)
Anti-SSB positive (, %)	8 (11.4)
Anti-U1RNP positive (, %)	27 (38.6)
Anti-Rib-P positive (, %)	29 (41.4)
Anti-nucleosome-A positive (, %)	24 (34.3)

Note: SD: standard deviation; SLE: systemic lupus erythematosus; SLEDAI: SLE disease activity index; IQR: interquartile range; dsDNA: double-stranded DNA.